Abstract
INTRODUCTION
Myocardial ischemia caused by coronary heart disease is a major cause of death globally. Currently, reperfusion therapy is the most effective way of treating acute myocardial infarction. However, myocardial ischemia/ reperfusion injury (MIRI) is an important factor affecting reperfusion treatment. 1 After cardiac muscle experiences ischemia, the ischemic myocardium and surrounding tissue will suffer more serious injury as restoring the blood supply can lead to energy failure, free radical generation, calcium overload, inflammation and other damage.
1,2
Therefore, preventing and reducing reperfusion damage has become the focus for attenuating myocardial infarction. Yindanxinnaotong capsule (YDXNTC) is a preparation made from Chinese herbal medicines, and has prominent curative effects on cardiovascular and cerebrovascular diseases. 3, 4 In clinical treatment, it is used, amongst others, for angina pectoris and arrhythmia. 3 However, studies on the pharmacological foundation and the mechanisms by which it works are poorly understood and rarely reported. In this study, an isolated heart perfusion rat model was used to imitate MIRI to investigate the protective effects of YDXNTC on MIRI. The protective effects of YDXNTC and the main components proportioning on rat myocardial cells (H9c2) were studied using an in vitro model of hypoxia/reoxygenation and hydrogen peroxide (H2O2) injury to investigate the possible underlying mechanisms.
MATERIALS AND METHODS

Reagents and instruments
Ginkgo biloba extract (GBE), ethanol extract of salvia miltiorrhiza (SM-E), aqueous extract of salvia miltiorrhiza (SM-H) and a mixed combination of other components in YDXNTC (MC) were provided by Guizhou Bailing Pharmaceutical Industry Co., Ltd. (Guizhou, China). Adult male Sprague-Dawley rats (270 ± 20) g were purchased from the Laboratory Animal Center of the Chinese People's Liberation Army Military Academy of Medical Sciences (Beijing, China). Superoxide dismutase (SOD), malondialdehyde (MDA) and lactate dehydrogenase (LDH) kits were from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) kits were from BG Products Inc. (Wichita, KS, USA). IL-1β was from Beijing North Biotechnology Research Institute (Beijing, China). IL-8, IL-18 and cardiac troponin T (cTnT) kits were from R&D Systems Inc. (Minneapolis, MN, USA). The Langendorff isolated heart perfusion system was from Panlab (Barcelona, Adebayor Ansel, Spain). DFM-96 γ radioimmunoassay counter equipment was from Hefei Zhongcheng Mechanical and Electrical Co. (Hefei, China). The microplate reader was from Thermo Fisher Scientific Inc. (Waltham, MA, USA). The H9c2 cell line was obtained from the Cell Resource Center of Peking Union Medical College (Beijing, China). Fetal bovine serum (FBS) was from Zhejiang Tianhang Biotechnology Co., Ltd., (Deqing, Zhejiang, China). Beta-actin and TLR-4 antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). HRP-labeled goat anti-mouse IgG was the product of Beijing Golden Bridge Biotechnology Co., Ltd. (Beijing, China). The electrophoresis device was from Bio-Rad Laboratories Inc. (Hercules, CA, USA).
Protective effect of YDXNTC and main components compatibility on MIRI Group design: Sprague-Dawley rats were divided into the following groups: (a) control; (b) model; (c) YDXNTC (GBE, 0.025 mg/mL; SM-E, 0.013 mg/ mL; SM-H, 0.031 mg/mL; and MC, 0.05 mg/mL); (d) GBE (GBE, 0.025 mg/mL); (e) SM-E (SM-E 0.04 mg/mL); (f) SM-H (SM-H, 0.4 mg/mL); (g) MC (MC, 0.05 mg/mL); (h) GBE and SM-E compatibility (GSEC) (GBE, 0.025 mg/mL and SM-E, 0.013 mg/ mL); (i) GBE and SM-H compatibility (GSHC) (GBE, 0.025 mg/mL and SM-H, 0.031 mg/mL); and (j) SM-E and SM-H compatibility (SEHC) (SM-E, 0.013 mg/mL and SM-H, 0.031 mg/mL). Six rats were allocated to each group. Ethical approval: all experimental procedures conformed with the guidelines of the Animal Care Committee of the China Academy of Chinese Medical Sciences. Induction of MIRI: sprague-Dawley rats were anesthetized with 20% urethane (1 g/kg), and the hearts were rapidly excised and mounted on a Langendorff apparatus and perfused at a constant rate with KrebsHenseleit buffer (K-HB) containing (in mmol/L): NaCl, 118; NaHCO3, 24; CaCl2-2H2O, 2.5; KCl, 4.7; KH2PO4, 1.2; MgSO4-7H2O, 1.2; and glucose, 11 (pH 7.4). 5, 6 Fine platinum electrodes were placed on the right atrium and apex of the left ventricle to record the electrocardiogram. After stabilization, the control group was perfused for 70 min; the model group was perfused for 10 min and then subjected to 30 min ischemia followed by 30 min reperfusion; and the drug groups were perfused for 10 min with K-HB containing drugs, followed by the same procedure as the model group. 5, 7 Electrocardiogram and coronary flow collection: the electrocardiogram was recorded throughout the experiment and cardiac arrest time, heart rebeat time, time to regain normal rhythm, and the incidence and duration of arrhythmias were determined. 7 Coronary blood was collected during stabilization at 5, 10, 15, 20, 25 and 30 min of the reperfusion period. Determination of SOD, MDA, myocardial enzymes and inflammatory factors: after reperfusion, hearts were removed from the device and homogenized before being centrifuged for 10 min at 100 ×g. The supernatant was stored at -20℃ . SOD, MDA, LDH, CK-MB, cTnI, cTnT, IL-1β, IL-8 and IL-18 were measured.
Protective effects and mechanisms of YDXNTC and main components proportioning in H9c2 cells
Group design: cells were divided into groups to serve as the control, model, YDXNTC and different ratios of GBE, SM-E and MC (Table 1-3). 8 Cell culture and treatment: cells were cultured in high-glucose DMEM supplemented with 10% FBS and a combination of penicillin-streptomycin in a humidified 5% CO2 atmosphere at 37℃ . On reaching 90% confluence, cells were treated with YDXNTC (21.88 μg/mL) and different concentrations of the proportioning drugs (Table 3) for 24 h before modeling. The hypoxia/reoxygenation injury model was established through hypoxia 3 h/oxygen 2 h, and the H2O2 injury model was established by the addition of 100 μM H2O2 for 1 h. 9, 10 Cell viability assay: cells were dispersed with trypsin and seeded at 8000-10 000 cells/well in a 96-well plate overnight before treatment. Subsequently, 200 μL MTT solution (5 mg/mL) was added and cells were incubated at 37℃ for 4 h. The supernatant was removed, and the insoluble formazan product was dissolved in 150 μL DMSO. Absorbance was measured with a microplate reader at a wavelength of 570 nm. Determination of SOD, MDA, cTnT and inflammatory factors: after model processing, the cell culture supernatant was collected and used to detect SOD, MDA, cTnT and inflammatory factors (IL-1β, IL-8 and IL-18). Western blotting analyses of TLR-4 expression: cells were treated with different drugs for 24 h before being subjected to model processing, after which, protein was extracted. TLR-4 expression was detected by western blotting.
Statistical analyses
All results are expressed as mean ± standard deviation (SD). Differences between groups were compared using one way ANOVA with the independent samples t-test. The incidence of ventricular tachycardia/ventricular fibrillation (VT/VF) between groups was compared using Fisher Chi-squared tests. Repeated measures analysis of variance was used to compare different time points between groups. A P-value of < 0.05 was considered statistically significant. Statistical tests were performed using SPSS 17.0 (IBM, Armonk, NY, USA).
RESULTS
Protective effects of YDXNTC and main components compatibility on MIRI Influence on VT/VF incidence: the results indicated that GBE and GSEC reduced VT/VF occurrence compared with the model group (P<0.05 and P<0.01, respectively; Figure 1 ). Impact on cardiac arrest time: cardiac arrest time increased after the addition of YDXNTC, SM-E, SM-H, MC, GSEC and SEHC compared with the model group (P<0.05, Table 4 ). Reduction in heart rebeat time: heart rebeat time decreased in all treatment groups compared with the model group (P<0.05, Table 4 ). Note: factor 1, 2, 3 and 4 are the experimental factors; level 1-9 are the test number. Table 2 Orthogonal factor levels (μg/mL) Notes: GBE: ginkgo biloba extract; SM-E: ethanol extract of salvia miltiorrhiza; MC: mixed compatibility of other ingredients in YDXNTC. 1, 2 and 3 are the different levels of the experimental factors.
Effect on time to regain normal rhythm: the time to regain normal rhythm decreased after pretreatment compared with the model group (P<0.05, Table 5 ).
Influence on arrhythmia duration
The duration of arrhythmia decreased with the addition of the study drugs compared with the model group (P<0.05, Table 5 ).
Improvement of coronary flow
The results showed that: (a) coronary flow of all groups at stabilization did not change (P>0.05; Table 6 . Pretreatment raised the activity of SOD for all drug groups except the SM-H, MC and GSHC groups (P<0.05, Table 6 ). The addition of drugs reduced MDA (P<0.05, Table 6 ). Notes: cardiac arrest time: heart stopped time-point less ischemia time-point; Heart rebeat time: heart restoring time-point less ischemia time-point. YDXNTC: all ingredients in the Yindanxinnaotong capsule (0.12 mg/mL, 20-day treatment course); GBE: ginkgo biloba extract (0.025 mg/mL); SM-E: ethanol extract of salvia miltiorrhiza (0.04 mg/mL); SM-H: aqueous extract of salvia miltiorrhiza (0.4 mg/mL); MC: mixed compatibility of other ingredients in YDXNTC (0.05 mg/mL); GSEC: GBE (0.025 mg/mL) and SM-E (0.013 mg/mL) compatibility; GSHC: GBE (0.025 mg/mL) and SM-H (0.031 mg/mL) compatibility; SEHC: SM-E (0.013 mg/mL) and SM-H (0.031 mg/ mL) compatibility. Table 5 Effect on heart function (s, n=6, x ±s) Notes: time to regain normal rhythm: timepoint for heart to restore normal rhythm less ischemia time-point; Arrhythmia duration time: sum of all arrhythmia times. YDXNTC: Yindanxinnaotong capsule (0.12 mg/mL, 20-day treatment course); GBE: ginkgo biloba extract (0.025 mg/mL); SM-E: ethanol extract of salvia miltiorrhiza (0.04 mg/mL); SM-H: aqueous extract of salvia miltiorrhiza (0.4 mg/mL); MC: mixed compatibility of other ingredients in YDXNTC (0.05 mg/mL); GSEC: GBE (0.025 mg/mL) and SM-E (0.013 mg/mL) compatibility; GSHC: GBE (0.025 mg/mL) and SM-H (0.031 mg/mL) compatibility; SE-HC: SM-E (0.013 mg/mL) and SM-H (0.031 mg/mL) compatibility.
a P<0.05 vs model group. Effect on LDH, CK-MB, cTnI and cTnT: an obvious reduction in LDH was evident after pretreatment with YDXNTC and SM-H (P<0.05, Table 7 ). Additionally, CK-MB also showed reduced levels after pretreatment with GBE, SM-E, SM-H and GSEC (P<0.05, Table  7 ). Of note was the decrease in cTnI and cTnT detected in the GSEC group compared with the model group (P<0.05, Table 7 ). Influence on inflammatory factors: compared with the model group, the addition of drugs evidently diminished IL-1β generation in all drug groups except for the SM-H group. Pretreatment with drugs resulted in decreased IL-8 levels apart from in the MC group. Additionally, the IL-18 level in all drug groups except for the MC and GSHC groups was obviously reduced (P< 0.05, Table 8 ).
Protective effects and mechanisms of YDXNTC and main components proportioning in H9c2 cells
Cell viability assay: YDXNTC raised cell viability in both hypoxia/reoxygenation and H2O2 injury cells (P< 0.05, Table 9 ). Ratios of GBE∶SM-E∶MC were 0∶1∶ 4, 4∶1∶0, 2∶1∶2 and 1∶0∶2 increased the viability of hypoxia/reoxygenation injury cells (P<0.05; Table 9 ). The viability of H2O2 injury cells improved with different proportions of GBE, SM-E and MC (P<0.05, Table 9). SOD and MDA determination: the result showed that pretreatment with YDXNTC increased SOD and decreased MDA levels induced by hypoxia/reoxygenation and H2O2 injury (P<0.05, Table 10 ). A marked increase in SOD and decrease in MDA levels was seen in hypoxia/reoxygenation injury cells when ratios of GBE ∶SM-E∶MC were 0∶1∶4, 1∶0∶2, 2∶1∶8, 4∶1∶0 and 2 ∶1∶2 (P<0.05, Table 10 ). A clear increase in SOD and reduced MDA was apparent with the different ratios of GBE, SM-E and MC after injury with H2O2 (P<0.05, Table 10 ). Examination of cTnT: YDXNTC and different proportions of GBE, SM-E and MC reduced cTnT in hypoxia/reoxygenation injury cells (P<0.05, Table  11 ). With H2O2 injury cells, cTnT decreased with the ratio of 2∶1∶2 (GBE∶SM-E∶MC) (P<0.05, Table 11).
Determination of inflammatory factors
Inflammatory factors released in hypoxia/reoxygenation injury cells: pretreatment with YDXNTC reduced the release of inflammatory factors (P<0.05, Table 12). IL-1β release decreased in the GBE, SM-E and MC groups at ratios of 0∶1∶4, 1∶0∶2, 2∶1∶8, 4∶1∶0 and 2∶1∶2 (P<0.05, Table 12 ). IL-8 release decreased at ratios of 0∶1∶4, 1∶0∶2, 2∶1∶8, 1∶1∶0 and 2∶1∶2 (GBE∶SM-E∶MC) (P<0.05, Table 12 ). Additionally, IL-18 was inhibited with the different proportioning ratios of GBE, SM-E and MC (P<0.05, Table 12 ). Inflammatory factor release of H2O2 injury cells: YDXNTC decreased IL-1β release in injured cells (P< 0.05, Table 12 ). A decrease in IL-1β was evident in the following ratios: 0∶1∶4, 1∶0∶2, 2∶1∶8, 4∶1∶0 and 2∶1 ∶2 (GBE∶SM-E∶MC) (P<0.05, Table 13 ). Ratios of 0: 1∶4, 1∶0∶2, 2∶1∶8 and 4∶1∶0 (GBE∶SM-E∶MC) decreased IL-8 release (P<0.05, Table 13 ). IL-18 release decreased at the following ratios: 0∶1∶4, 1∶0∶2 and 4∶ 1∶0 (GBE∶SM-E∶MC) (P<0.05, Table 13 ).
Expression of TLR-4
YDXNTC decreased TLR-4 expression in hypoxia/reoxygenation and H2O2 injury cells (P<0.05; Figure 5 ). The different proportions of main components also reduced TLR-4 expression induced by hypoxia/reoxygenation injury (P<0.05; Figure 5 ). TLR-4 expression in- duced by H2O2 injury was down-regulated when ratios of the main components were 0∶1∶4, 1∶0∶2, 1∶1∶0, 4 ∶1∶0 and 2∶1∶2 (P<0.05, Figure 5 ).
DISCUSSION
Coronary heart disease is one of the common cardiovascular diseases, and has a high incidence. Basic research and clinical treatments for cardiovascular diseases are in continuous development and great progress has been made.
1,11
Currently, treatment for coronary heart diseases mainly lie in thrombolysis, intervention and surgical bypass. 12 Unfortunately, MIRI is a problem regardless of the therapy used. 12 MIRI can be aggravated when the blood supply is recovering. 13 Therefore, the prevention and treatment of MIRI is a critical issue that needs to be resolved. 14 YDXNTC is refined from several kinds of natural Chinese herbal medicines. 15 It is used for angina pectoris, Table 7 Effect on myocardial enzyme markers (n=6, x ±s) Notes: LDH: lactic dehydrogenase; CK-MB: creatine kinase-MB; cTnI and cTnT: cardiac troponin I and T. YDXNTC: Yindanxinnaotong capsule (0.12 mg/mL, 20-day treatment course); GBE: ginkgo biloba extract (0.025 mg/mL); SM-E: ethanol extract of salvia miltiorrhiza (0.04 mg/mL); SM-H: aqueous extract of salvia miltiorrhiza (0.4 mg/mL); MC: mixed compatibility of other ingredients in YDXNTC (0.05 mg/mL); GSEC: GBE (0.025 mg/mL) and SM-E (0.013 mg/mL) compatibility; GSHC: GBE (0.025 mg/mL) and SM-H (0.031 mg/mL) compatibility; SEHC: SM-E (0.013 mg/mL) and SM-H (0.031 mg/mL) compatibility. hypertension and stroke caused by Qi stagnation, blood stasis and phlegm obstruction. 16 YDXNTC can increase coronary blood flow and improve myocardial ischemic and anoxic conditions. 16 No research has yet been reported on YDXNTC's pharmacological foundation and underlying mechanisms. In this study, Langendorff isolated hearts were used to establish a rat model of MIRI and the protective effects of YDXNTC and the dominant ingredients were investigated. The mechanisms for the protective effects of YDXNTC were studied using an in vitro model of hypoxia/reoxygenation and H2O2 injury with rat myocardial cells (H9c2). The following results were observed: (a) YDXNTC improved heart function, coronary flow and SOD, and decrease MDA and the release of inflammatory factors, and myocardial enzymes. These findings indicate that YDXNTC has cardioprotective effects during MIRI; (b) Main components compatibility exhibited an obvious effect on heart function and coronary flow. A remarkable inhibition of MDA and increase in SOD were observed. Additionally, the release of inflammatory factors reduced, and cardiac troponin decreased, in the GSEC group. This finding suggests that the main components compatibility may have cardioprotective properties; (c) Cell viability and the SOD level in hypoxia/reoxygenation and H2O2 injury models were elevated by YDXNTC. YDXNTC also decreased MDA levels and the release of inflammatory factors in the injured cells. Cell cardiac troponin release decreased with YDXNTC after cells were injured by hypoxia/reoxygenation. These findings indicate that YDXNTC also had a protective effect on hypoxic injuries; (d) In the hypoxia/reoxygenation and H2O2 injury models, there was an increase in cell viability and SOD levels by pretreatment with different proportions of the main components. A reduction in MDA levels, the release of inflammatory factors and cardiac troponin levels were observed in the proportioning groups. These findings suggest the cardioprotective effects of the main components proportioning; (e) YDXNTC resulted in the down-regulation of TLR-4 expression in hypoxia/reoxygenation and H2O2 injured cells. Main components proportioning also reduced TLR-4 expression. These findings suggest that the mechanism by which YDXNTC protects myocardial cells from ischemic injury may be related to regulating the Toll-like receptor pathway.
In conclusion, this study supports findings of the protective efficacy of YDXNTC on rat models of myocardial ischemia/reperfusion injury. The mechanism behind the protective effects may be related to the actions of antioxidants, anti-inflammatory damage, alleviating calcium overload and Toll-like receptor regulation. Further study is required to confirm these findings. 
